- Trial phase
- Approved; post-market Phase 3 long-term safety extension completed
- Time to market
- Already approved and on the market, FDA approval recorded April 28, 2022 (per local FDA catalyst records)
- Why 3/10
- Camzyos is already approved (FDA approval recorded 2022-04-28) and commercialized with NO hard, dated regulatory catalyst in the next ~12 months, the only pending item is a Phase 3 long-term safety extension (NCT03723655) that completed 2026-01-16 with results not yet posted and no announced readout date, so as one Growth-Portfolio drug inside a mega-cap it scores 3.
Watch for two things: (1) BMY posting MAVA-LTE long-term safety data for Camzyos (safety of the myosin-inhibitor class is the key risk) and quarterly Growth Portfolio/Camzyos sales commentary; and (2) the bigger HCM binary this year is actually the competitor's, Cytokinetics' aficamten (MYQORZO) has a PDUFA on 2026-11-14, which will set the competitive narrative for Camzyos. Do not expect a Camzyos-specific binary to move BMY much on its own.
Price Chart
Executive Summary
Camzyos (mavacamten) is Bristol Myers Squibb's first-in-class treatment for hypertrophic cardiomyopathy, approved by the FDA on April 28, 2022 per local FDA catalyst records, an already-commercialized drug with no pending regulatory decision. The only open item is a 314-patient Phase 3 long-term safety extension (NCT03723655) completed January 2026 with results not yet posted. It faces direct competition from Cytokinetics' aficamten (MYQORZO), already approved in the US/EU/China for obstructive HCM, which posted positive Phase 3 data in non-obstructive HCM and has a Nov 14, 2026 PDUFA for a further label expansion.
How It Works
Camzyos (mavacamten) is an oral small-molecule drug used to treat hypertrophic cardiomyopathy, a genetic condition, per the trial records, in which the heart muscle thickens and contracts too forcefully and can block blood flow out of the heart. It is a cardiac myosin inhibitor: it slows the heart muscle's over-active contraction by dampening the 'motor' protein that powers each heartbeat. (Note: external web sources were unreachable this session, so this mechanism description relies on the drug's established public profile plus the local trial/FDA records.)
Trial Status
The 314-patient Phase 3 long-term safety extension study (NCT03723655, MAVA-LTE) in adults who completed the MAVERICK-HCM or EXPLORER-HCM trials was completed 2026-01-16 (actual primary completion); local records show results not yet posted (hasResults=false), with no announced readout date.
The Two-Sided Case
Upcoming Catalysts
- Posting of MAVA-LTE (NCT03723655) long-term safety results, no date announced, results 'pending'
- Competitor read-through: aficamten sNDA PDUFA 2026-11-14 (Cytokinetics, CYTK), sets the competitive narrative for the HCM class
- BMY quarterly earnings (next after the 2026-07-30 Q2 release) for Camzyos / Growth Portfolio sales commentary
- Any label-expansion or new-trial announcements for mavacamten from BMY
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report